TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA PATIENTS WITH DRUG OF FIRST GENERATION – «IMATINIB» IN TAJIKISTAN

K.Z. Urakov, G.B. Hojieva, V.Y. Melnikova, A.T. Shamsov

Chair of Internal Medicine №3 Avicenna TSMU

A study of 46 patients with chronic myelogenous leukemia who have taken drugs of the first generation «Imatinib» for 5 years is conducted. Treatment efficacy was assessed by achieving of hematologic and cytogenetic responses. In 3 cases, there was a break in treatment.

Risk for disease progression by Sokalin patients with chronic myelogenous leukemia at chronic phase were as follows: low – in 9 (50,0%) patients, intermediate – in 4 (22,2%) and high – in 5 patients (27,7%). At acceleration phase: low – in 10 (35,7%), intermediate –11 (39,2%) and high – in 7 (25,0%) patients. Five-year overall survival of patients at chronic phase and accelerated phase of chronic myelogenousleukemia with starting therapy by tyrosine kinase inhibitors Imatinib first generation was 78.0%. Imatinibcertainly is a drug of choice at the outset of the disease.

Keywords: chronic myelogenous leukemia, the stage of acceleration , blast crisis phase , Imatinib.

Download file:

---